Dr Turner presents, at a press conference at ASCO 2015, the phase III registration study PALOMA-3, which reports that adding the investigational targeted agent palbociclib to standard hormonal therapy (fulvestrant) more than doubled the duration of disease control, delaying disease progression by roughly five months in women with previously treated, hormone receptor-positive, human epidermal growth factor receptor 2 negative (HR /HER2-) advanced breast cancer.

Read the news article and watch the interview for more.